Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4204—Epidermal growth factor receptors [EGFR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Application Number	Priority Date	Filing Date	Title
US201862620414P	2018-01-22	2018-01-22
US201862620706P	2018-01-23	2018-01-23
US201862656233P	2018-04-11	2018-04-11
US201862724171P	2018-08-29	2018-08-29
US201862735627P	2018-09-24	2018-09-24
US201862736727P	2018-09-26	2018-09-26
PCT/US2019/014478WO2019144095A1 (en)	2018-01-22	2019-01-22	Methods of use for car t cells

Publication Number	Publication Date
SG11202006886VAtrue SG11202006886VA (en)	2020-08-28

Family

ID=67299784

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202006886VASG11202006886VA (en)	2018-01-22	2019-01-22	Methods of use for car t cells

Country Status (11)

Country	Link
US (4)	US11779602B2 (en)
EP (2)	EP3743082A4 (en)
JP (3)	JP7417542B2 (en)
CN (3)	CN120154716A (en)
AU (2)	AU2019209428B2 (en)
BR (1)	BR112020014913A2 (en)
CA (2)	CA3089319A1 (en)
IL (1)	IL276131A (en)
SG (1)	SG11202006886VA (en)
TW (1)	TW201940182A (en)
WO (2)	WO2019144095A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3653212B1 (en)	2012-12-20	2023-04-26	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US12144850B2 (en)	2016-04-08	2024-11-19	Purdue Research Foundation	Methods and compositions for car T cell therapy
WO2018148224A1 (en)	2017-02-07	2018-08-16	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
US11850262B2 (en)	2017-02-28	2023-12-26	Purdue Research Foundation	Compositions and methods for CAR T cell therapy
SG11202006886VA (en)	2018-01-22	2020-08-28	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Methods of use for car t cells
CN111936518A (en)*	2018-02-06	2020-11-13	西雅图儿童医院（Dba西雅图儿童研究所）	Fluorescein-specific CARs exhibiting optimal T cell function for FL-PLE labeled tumors
CA3091674A1 (en)*	2018-02-23	2019-08-29	Endocyte, Inc.	Sequencing method for car t cell therapy
EP3775231A2 (en)	2018-04-12	2021-02-17	Umoja Biopharma, Inc.	Viral vectors and packaging cell lines
WO2022099153A1 (en)*	2020-11-09	2022-05-12	St. Jude Children's Research Hospital	Novel vhl small molecule probes
CA3200076A1 (en)*	2020-11-30	2022-06-02	Purdue Research Foundation	Combinations of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of treating cancer using the same
EP4032910A1 (en)*	2021-01-22	2022-07-27	ETH Zurich	Bispecific binding agent that binds to cd3 and a fluorophore
KR20240133796A (en)	2021-12-17	2024-09-04	우모자 바이오파마 인코포레이티드	Cytotoxic innate lymphoid cells and uses thereof
KR20250022800A (en)	2022-06-10	2025-02-17	우모자 바이오파마 인코포레이티드	Engineered stem cells and their uses
WO2024081824A2 (en)*	2022-10-14	2024-04-18	University Of Washington	Synthetic intermediates for universal chimeric antigen receptor immune cell therapies
WO2024097992A2 (en)	2022-11-04	2024-05-10	Umoja Biopharma, Inc.	Particles displaying adhesion-molecule fusions
CN116376828B (en)*	2023-06-02	2023-08-11	成都云测医学生物技术有限公司	Method for inducing CD4+ T cells to generate Treg cells and application
CN117659205B (en)*	2023-12-05	2024-12-03	北京同立海源生物科技有限公司	A coupling method for sorting activated magnetic beads and its application
WO2025129084A1 (en)	2023-12-13	2025-06-19	Umoja Biopharma, Inc.	Engineered induced stem cell derived myeloid cells and methods of differentiating and using same
CN118374444A (en)*	2024-05-24	2024-07-23	中国人民解放军军事科学院军事医学研究院	A method for producing human blood cells in vitro using bone marrow organoids

Family Cites Families (402)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE101203T1 (en)	1985-01-28	1994-02-15	Xoma Corp	ARAB PROMOTERS AND METHODS FOR THE PRODUCTION OF POLYPEPTIDES INCLUDING CECROPINES BY MICROBIOLOGICAL METHODS.
US4690915A (en)	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
IN165717B (en)	1986-08-07	1989-12-23	Battelle Memorial Institute
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US6004781A (en)	1988-01-22	1999-12-21	The General Hospital Corporation	Nucleic acid encoding Ig-CD4 fusion proteins
IL86278A (en)	1988-05-04	2003-06-24	Yeda Res & Dev	Endowing cells with antibody specificity using chimeric t cell receptor
US5906936A (en)	1988-05-04	1999-05-25	Yeda Research And Development Co. Ltd.	Endowing lymphocytes with antibody specificity
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en)	1989-02-23	2002-06-18	Genentech, Inc.	Hybrid immunoglobulins
US5216132A (en)	1990-01-12	1993-06-01	Protein Design Labs, Inc.	Soluble t-cell antigen receptor chimeric antigens
US20020004052A1 (en)	1990-05-08	2002-01-10	David Berd	Composition comprising a tumor cell extract and method of using the composition
US5914109A (en)	1990-06-15	1999-06-22	New York University	Heterohybridomas producing human monoclonal antibodies to HIV-1
US20020111474A1 (en)	1990-12-14	2002-08-15	Capon Daniel J.	Chimeric chains for receptor-associated signal transduction pathways
US6319494B1 (en)	1990-12-14	2001-11-20	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
JP3242916B2 (en)	1990-12-14	2001-12-25	セルジェネシス，インコーポレイティド	Chimeric chains for receptor-related signal transduction systems
US6407221B1 (en)	1990-12-14	2002-06-18	Cell Genesys, Inc.	Chimeric chains for receptor-associated signal transduction pathways
NZ241855A (en)	1991-03-07	1994-04-27	Gen Hospital Corp	Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor
US6004811A (en)	1991-03-07	1999-12-21	The Massachussetts General Hospital	Redirection of cellular immunity by protein tyrosine kinase chimeras
US7049136B2 (en)	1991-03-07	2006-05-23	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
US5843728A (en)	1991-03-07	1998-12-01	The General Hospital Corporation	Redirection of cellular immunity by receptor chimeras
US5851828A (en)	1991-03-07	1998-12-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6753162B1 (en)	1991-03-07	2004-06-22	The General Hospital Corporation	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5912170A (en)	1991-03-07	1999-06-15	The General Hospital Corporation	Redirection of cellular immunity by protein-tyrosine kinase chimeras
WO1992015671A1 (en)	1991-03-08	1992-09-17	Cytomed, Inc.	Soluble cd28 proteins and methods of treatment therewith
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
ATE194494T1 (en)	1991-10-21	2000-07-15	Cell Genesys Inc	COMBINED CELLULAR AND IMMUNOSUPRESSIVE THERAPIES
IL104570A0 (en)	1992-03-18	1993-05-13	Yeda Res & Dev	Chimeric genes and cells transformed therewith
US8211422B2 (en)	1992-03-18	2012-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric receptor genes and cells transformed therewith
US5372930A (en)	1992-09-16	1994-12-13	The United States Of America As Represented By The Secretary Of The Navy	Sensor for ultra-low concentration molecular recognition
US7105159B1 (en)	1992-11-05	2006-09-12	Sloan-Kettering Institute For Cancer Research	Antibodies to prostate-specific membrane antigen
US6953668B1 (en)	1992-11-05	2005-10-11	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen
EP1757695A3 (en)	1992-11-05	2008-02-27	Sloan Kettering Institute For Cancer Research	Prostate-specific membrane antigen
US5861156A (en)	1993-01-08	1999-01-19	Creative Biomolecules	Methods of delivering agents to target cells
JPH08511000A (en)	1993-04-06	1996-11-19	フレッドハッチンソンキャンサーリサーチセンター	Chimeric cytokine receptor in lymphocytes
US6051427A (en)	1993-06-11	2000-04-18	Cell Genesys, Inc.	Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5834256A (en)	1993-06-11	1998-11-10	Cell Genesys, Inc.	Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5525503A (en)	1993-09-28	1996-06-11	Dana-Farber Cancer Institute, Inc.	Signal transduction via CD28
US5935818A (en)	1995-02-24	1999-08-10	Sloan-Kettering Institute For Cancer Research	Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
ES2185705T3 (en)	1994-05-02	2003-05-01	Bernd Groner	BIFUNCTIONAL PROTEIN, PREPARATION AND USE.
US7354587B1 (en)	1994-07-06	2008-04-08	Immunomedics, Inc.	Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US5798100A (en)	1994-07-06	1998-08-25	Immunomedics, Inc.	Multi-stage cascade boosting vaccine
US5716614A (en)	1994-08-05	1998-02-10	Molecular/Structural Biotechnologies, Inc.	Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
EP0787188A1 (en)	1994-11-01	1997-08-06	Targeted Genetics Corporation	Chimeric receptors for the generation of selectively-activatable t h?-independent cytotoxic t cells
US5837544A (en)	1995-02-02	1998-11-17	Cell Genesys, Inc.	Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5712149A (en)	1995-02-03	1998-01-27	Cell Genesys, Inc.	Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en)	1995-02-06	2000-08-15	Cell Genesys, Inc.	Multispecific chimeric receptors
DE69635801T2 (en)	1995-02-24	2006-11-02	Sloan-Kettering Institute For Cancer Research	PROSTATE-SPECIFIC MEMBRANES ANTIGEN AND ITS APPLICATIONS
US5830755A (en)	1995-03-27	1998-11-03	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	T-cell receptors and their use in therapeutic and diagnostic methods
WO1997004752A1 (en)	1995-07-26	1997-02-13	Duramed Pharmaceuticals, Inc.	Pharmaceutical compositions of conjugated estrogens and methods for their use
GB9526131D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Recombinant chimeric receptors
WO1997034634A1 (en)	1996-03-20	1997-09-25	Sloan-Kettering Institute For Cancer Research	Single chain fv constructs of anti-ganglioside gd2 antibodies
US6261787B1 (en)	1996-06-03	2001-07-17	Case Western Reserve University	Bifunctional molecules for delivery of therapeutics
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20020018783A1 (en)	1997-03-20	2002-02-14	Michel Sadelain	Fusion proteins of a single chain antibody and cd28 and uses thereof
DE69838843D1 (en)	1997-06-11	2008-01-24	Univ New York	PRENYLCYSTEIN CARBOXYL METHYL TRANSFERASE, DNA SELF-CODED, AND A METHOD OF SEARCHING FOR INHIBITORS
US6759243B2 (en)	1998-01-20	2004-07-06	Board Of Trustees Of The University Of Illinois	High affinity TCR proteins and methods
US20090011984A1 (en)	1998-02-23	2009-01-08	Seppo Yla-Herttuala	Biotin-binding receptor molecules
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
CA2327314A1 (en)	1998-05-19	1999-11-25	Avidex Limited	Soluble t cell receptor
CA2343156A1 (en)	1998-09-04	2000-03-16	Sloan-Kettering Institute For Cancer Research	Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6410319B1 (en)	1998-10-20	2002-06-25	City Of Hope	CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
DK1124568T3 (en)	1998-10-21	2008-01-02	Altor Bioscience Corp	Polyspecific Binding Molecules and Uses thereof
US7217421B1 (en)	1998-11-03	2007-05-15	Cell Genesys, Inc.	Cancer-associated antigens and methods of their identification and use
US6521602B1 (en)	1999-03-01	2003-02-18	Gpc Biotech Inc.	Anti-neoplastic compositions and uses thereof
JP2002541845A (en)	1999-04-16	2002-12-10	セルテックセラピューティックスリミテッド	Synthetic transmembrane component
US6699972B1 (en)	1999-06-25	2004-03-02	Academia Sinica	Chimeric protein and method of controlling tumor growth using the protein
WO2001049318A1 (en)	2000-01-03	2001-07-12	Tr Associates, L.L.C.	Novel chimeric proteins and methods for using the same
US7572891B2 (en)	2000-02-14	2009-08-11	The Regents Of The University Of California	Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
US6770749B2 (en)	2000-02-22	2004-08-03	City Of Hope	P53-specific T cell receptor for adoptive immunotherapy
HRP20020787B1 (en)	2000-03-31	2012-06-30	Purdue Research Foundation	TREATMENT PROCEDURE USING THE LIGAND-IMMUNOGEN COMPLEX
WO2001091625A2 (en)	2000-04-21	2001-12-06	Rutgers, The State University Of New Jersey	Methods and compositions for the diagnosis of schizophrenia
US6524572B1 (en)	2000-06-26	2003-02-25	Rainbow Therapeutic Company	Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy
DE60133287T2 (en)	2000-07-31	2009-03-26	Green Peptide Co., Ltd., Kurume	TUMOR ANTIGEN
US7666424B2 (en)	2001-10-17	2010-02-23	Sloan-Kettering Institute For Cancer Research	Methods of preparing and using single chain anti-tumor antibodies
DE60122765D1 (en)	2000-11-07	2006-10-12	Hope City	CD19-SPECIFIC TARGETED IMMUNOCELLS
US20020132983A1 (en)	2000-11-30	2002-09-19	Junghans Richard P.	Antibodies as chimeric effector cell receptors against tumor antigens
US7723111B2 (en)	2001-03-09	2010-05-25	The United States Of America As Represented By The Department Of Health And Human Services	Activated dual specificity lymphocytes and their methods of use
US7070995B2 (en)	2001-04-11	2006-07-04	City Of Hope	CE7-specific redirected immune cells
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en)	2001-04-30	2009-04-07	City Of Hope	Chimeric immunoreceptor useful in treating human gliomas
EP1392818A4 (en)	2001-04-30	2005-01-05	Hope City	CHIMERIC IMMUNORECTOR USE IN THE TREATMENT OF HUMAN CANCER
US20070031438A1 (en)	2001-12-10	2007-02-08	Junghans Richard P	Antibodies as chimeric effector cell receptors against tumor antigens
US7939059B2 (en)	2001-12-10	2011-05-10	California Institute Of Technology	Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en)	2002-03-07	2003-09-11	Gruenberg Micheal L.	Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en)	2002-05-28	2008-11-04	Sloan-Kettering Institute For Cancer Research	Nucleic acids encoding chimeric T cell receptors
EP2181595A1 (en)	2002-08-16	2010-05-05	Yeda Research And Development Company Ltd.	Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
US8809504B2 (en)	2002-09-03	2014-08-19	Vit Lauermann	Inhibitor which is deactivatable by a reagent produced by a target cell
DE10244457A1 (en)	2002-09-24	2004-04-01	Johannes-Gutenberg-Universität Mainz	Process for the rational mutagenesis of alpha / beta T-cell receptors and corresponding mutated MDM2 protein-specific alpha / beta T-cell receptors
US20060018878A1 (en)	2003-03-11	2006-01-26	City Of Hope	Dual antigen specific T cells with trafficking ability
US20050129671A1 (en)	2003-03-11	2005-06-16	City Of Hope	Mammalian antigen-presenting T cells and bi-specific T cells
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en)	2003-05-06	2008-03-25	Syntonix Pharmaceuticals, Inc.	Immunoglobulin chimeric monomer-dimer hybrids
US20050113564A1 (en)	2003-11-05	2005-05-26	St. Jude Children's Research Hospital	Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
US20130266551A1 (en)	2003-11-05	2013-10-10	St. Jude Children's Research Hospital, Inc.	Chimeric receptors with 4-1bb stimulatory signaling domain
US8652484B2 (en)	2004-02-13	2014-02-18	Immunomedics, Inc.	Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US7196062B2 (en)	2004-02-18	2007-03-27	Wisconsin Alumni Research Foundation	Method for treating glaucoma
DE602005015687D1 (en)	2004-03-02	2009-09-10	Cellectar Inc	PHOSPHOLIPIDE ANALOGUE FOR THE TREATMENT OF CANCER
ATE443084T1 (en)	2004-07-10	2009-10-15	Fox Chase Cancer Ct	GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES:
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
WO2006036445A2 (en)	2004-09-24	2006-04-06	Trustees Of Dartmouth College	Chimeric nk receptor and methods for treating cancer
ATE549398T1 (en)	2004-10-08	2012-03-15	Us Gov Health & Human Serv	ADOPTIVE IMMUNOTHERAPY WITH INCREASED T-LYMPHOCYTE LIFESPAN
CA2587766A1 (en)	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
WO2007044033A2 (en)	2004-12-07	2007-04-19	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
US20070036773A1 (en)	2005-08-09	2007-02-15	City Of Hope	Generation and application of universal T cells for B-ALL
CA2632094C (en)	2005-12-02	2015-01-27	Wayne A. Marasco	Carbonic anhydrase ix (g250) antibodies and methods of use thereof
US7919079B2 (en)	2006-03-31	2011-04-05	Biosante Pharmaceuticals, Inc.	Cancer immunotherapy compositions and methods of use
EP3805269A1 (en)	2006-06-12	2021-04-14	Aptevo Research and Development LLC	Single-chain multivalent binding proteins with effector function
US20080051380A1 (en)	2006-08-25	2008-02-28	Auerbach Alan H	Methods and compositions for treating cancer
EP1900752A1 (en)	2006-09-15	2008-03-19	DOMPE' pha.r.ma s.p.a.	Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US20100105136A1 (en)	2006-10-09	2010-04-29	The General Hospital Corporation	Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US9334330B2 (en)	2006-10-10	2016-05-10	Universite De Nantes	Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
WO2008057437A2 (en)	2006-11-03	2008-05-15	Purdue Research Foundation	Ex vivo flow cytometry method and device
JP5188504B2 (en)	2006-11-13	2013-04-24	サンガモバイオサイエンシズインコーポレイテッド	Methods and compositions for modification of the human glucocorticoid receptor locus
US20080131415A1 (en)	2006-11-30	2008-06-05	Riddell Stanley R	Adoptive transfer of cd8 + t cell clones derived from central memory cells
US8748405B2 (en)	2007-01-26	2014-06-10	City Of Hope	Methods and compositions for the treatment of cancer or other diseases
EP2123754B1 (en)	2007-01-30	2011-04-06	Forerunner Pharma Research Co., Ltd.	CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
ES2926805T3 (en)	2007-01-31	2022-10-28	Yeda Res & Dev	Genetically engineered and redirected regulatory T cells and their use in suppressing autoimmune and inflammatory diseases
US8859229B2 (en)	2007-02-02	2014-10-14	Yale University	Transient transfection with RNA
US8865169B2 (en)	2007-02-20	2014-10-21	Tufts University	Methods and systems for multi-antibody therapies
CA2682527C (en)	2007-03-30	2017-07-11	Memorial Sloan-Kettering Cancer Center	Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
CN101820913A (en)	2007-08-09	2010-09-01	第一三共株式会社	Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
WO2009091826A2 (en)	2008-01-14	2009-07-23	The Board Of Regents Of The University Of Texas System	Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009117117A1 (en)	2008-03-19	2009-09-24	Altor Bioscience Corporation	T cell receptor fusions and conjugates and methods of use there of
EP2279253B1 (en)	2008-04-09	2016-11-16	Maxcyte, Inc.	Engineering and delivery of therapeutic compositions of freshly isolated cells
RU2531754C2 (en)	2008-04-11	2014-10-27	ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US	Immunotherapeutic agent combined with cd37, and its combination with bifunctional chemotherapeutic agent
US20090324630A1 (en)	2008-04-21	2009-12-31	Jensen Michael C	Fusion multiviral chimeric antigen
ES2961498T3 (en)	2008-08-26	2024-03-12	Hope City	Method and compositions for enhanced performance of anti-tumor effect of T cells
CA2737496A1 (en)	2008-09-17	2010-03-25	Endocyte, Inc.	Folate receptor binding conjugates of antifolates
GB2467704B (en)	2008-11-07	2011-08-24	Mlc Dx Inc	A method for determining a profile of recombined DNA sequences in T-cells and/or B-cells
US9283184B2 (en)	2008-11-24	2016-03-15	Massachusetts Institute Of Technology	Methods and compositions for localized agent delivery
US20110178279A1 (en)	2009-08-03	2011-07-21	Williams John C	Development of masked therapeutic antibodies to limit off-target effects: application to anti-egfr antibodies
US8877199B2 (en)	2009-05-15	2014-11-04	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	B cell surface reactive antibodies
US20100322909A1 (en)	2009-06-17	2010-12-23	The University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Th1-associated micrornas and their use for tumor immunotherapy
AU2010301042B2 (en)	2009-10-01	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2796379A1 (en)	2009-10-27	2011-05-05	Immunicum Ab	Method for proliferation of antigen-specific t cells
US9273283B2 (en)	2009-10-29	2016-03-01	The Trustees Of Dartmouth College	Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en)	2009-10-29	2011-05-19	Trustees Of Dartmouth College	T cell receptor-deficient t cell compositions
DK2496698T3 (en)	2009-11-03	2019-04-15	Hope City	TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
SG181559A1 (en)	2009-12-08	2012-07-30	Wolf Wilson Mfg Corp	Improved methods of cell culture for adoptive cell therapy
US8956860B2 (en)	2009-12-08	2015-02-17	Juan F. Vera	Methods of cell culture for adoptive cell therapy
AU2011209743B2 (en)	2010-01-28	2016-03-10	The Children's Hospital Of Philadelphia	A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
WO2011097477A1 (en)	2010-02-04	2011-08-11	The Trustees Of The University Of Pennsylvania	Icos critically regulates the expansion and function of inflammatory human th17 cells
WO2011100566A2 (en)	2010-02-12	2011-08-18	Oncomed Pharmaceuticals, Inc.	Methods for identifying and isolating cells expressing a polypeptide
SA111320200B1 (en)	2010-02-17	2014-02-16	ديبيوفارم اس ايه	Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
EP3202410B1 (en)	2010-04-14	2020-03-25	Roger Williams Medical Center	Methods and compositions for treating hiv
EP2566954B2 (en)	2010-05-04	2022-11-02	Yeda Research and Development Co. Ltd.	Immunotherapy using redirected allogeneic cells
US9089520B2 (en)	2010-05-21	2015-07-28	Baylor College Of Medicine	Methods for inducing selective apoptosis
US9242014B2 (en)	2010-06-15	2016-01-26	The Regents Of The University Of California	Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9163258B2 (en)	2010-07-23	2015-10-20	Fred Hutchinson Cancer Research Center	Method for the treatment of obesity
DE102010036122A1 (en)	2010-09-01	2012-03-01	Nora Systems Gmbh	Flooring
EP2614143B1 (en)	2010-09-08	2018-11-07	Baylor College Of Medicine	Immunotherapy of non-small lung cancer using genetically engineered gd2-specific t cells
NO3012268T3 (en)	2010-09-08	2018-04-14
WO2012136231A1 (en)	2010-09-08	2012-10-11	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Interleukin 15 as selectable marker for gene transfer in lymphocytes
EP3533802B1 (en)	2010-09-21	2021-03-17	The United States of America, as represented by The Secretary, Department of Health and Human Services	Anti-ssx-2 t cell receptors and related materials and methods of use
CN103154257A (en)	2010-09-26	2013-06-12	大玉企业有限公司	Method of recombinant macromolecular production
US9845362B2 (en)	2010-10-08	2017-12-19	The University Of North Carolina At Charlotte	Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
WO2012054825A1 (en)	2010-10-22	2012-04-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-mage-a3 t cell receptors and related materials and methods of use
WO2012076059A1 (en)	2010-12-09	2012-06-14	Stichting Het Nederlands Kanker Instituut	Immune restricted peptides with increased efficacy
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
US9233125B2 (en)	2010-12-14	2016-01-12	University Of Maryland, Baltimore	Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
AU2012207356A1 (en)	2011-01-18	2013-08-01	The Trustees Of The University Of Pennsylvania	Compositions and methods for treating cancer
WO2012109659A1 (en)	2011-02-11	2012-08-16	Memorial Sloan-Kettering Cancer Center	Hla-restricted, peptide-specific antigen binding proteins
EP2689010B1 (en)	2011-03-23	2020-11-18	Fred Hutchinson Cancer Research Center	Method and compositions for cellular immunotherapy
EP2502934B1 (en)	2011-03-24	2018-01-17	Universitätsmedizin der Johannes Gutenberg-Universität Mainz	Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
EA201391449A1 (en)	2011-04-01	2014-03-31	Мемориал Слоан-Кеттеринг Кэнсер Сентер	ANTIBODIES AGAINST CYTOSOL PEPTIDES
PT2694549T (en)	2011-04-08	2018-11-22	Us Health	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
EP2697367B1 (en)	2011-04-13	2018-12-19	Immunicum AB	Method for proliferation of antigen-specific t cells
US9492529B2 (en)	2011-04-13	2016-11-15	Immunicum Ab	Method for priming of T cells
CN105968209B (en)	2011-04-19	2021-08-03	美国政府(由卫生和人类服务部的部长所代表)	Human monoclonal antibody specific for Glypican 3 and use thereof
GB201108236D0 (en)	2011-05-17	2011-06-29	Ucl Business Plc	Method
CN107266584B (en)	2011-07-29	2022-05-13	宾夕法尼亚大学董事会	Transducible co-stimulatory receptors
CN103889452B (en)	2011-08-23	2017-11-03	罗切格利卡特公司	Bispecific antibody specific for T cell activating antigen and tumor antigen and method of use
WO2013033626A2 (en)	2011-08-31	2013-03-07	Trustees Of Dartmouth College	Nkp30 receptor targeted therapeutics
PT3392270T (en)	2011-09-15	2020-11-24	Us Health	T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
SG11201400527XA (en)	2011-09-16	2014-04-28	Univ Pennsylvania	Rna engineered t cells for the treatment of cancer
WO2013040371A2 (en)	2011-09-16	2013-03-21	Baylor College Of Medicine	Targeting the tumor microenvironment using manipulated nkt cells
US9708384B2 (en)	2011-09-22	2017-07-18	The Trustees Of The University Of Pennsylvania	Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
EP2765193B1 (en)	2011-10-07	2017-08-09	Mie University	Chimeric antigen receptor
CA2851795C (en)	2011-10-20	2018-11-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-cd22 chimeric antigen receptors
JP6074435B2 (en)	2011-10-26	2017-02-01	ナショナルキャンサーセンター	Mutant CTLA4 gene-transferred T cell and anticancer immunotherapeutic composition containing the same
US9226936B2 (en)	2011-10-28	2016-01-05	The Wistar of Anatomy and Biology	Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
WO2013063419A2 (en)	2011-10-28	2013-05-02	The Trustees Of The University Of Pennsylvania	A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013067492A1 (en)	2011-11-03	2013-05-10	The Trustees Of The University Of Pennsylvania	Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en)	2011-11-08	2014-10-30	The Trustees Of The University Of Pennsylvania	Glypican-3-specific antibody and uses thereof
AU2012335073B2 (en)	2011-11-11	2017-08-17	Fred Hutchinson Cancer Center	Cyclin A1-targeted T-cell immunotherapy for cancer
WO2013088446A1 (en)	2011-12-16	2013-06-20	Targetgene Biotechnologies Ltd	Compositions and methods for modifying a predetermined target nucleic acid sequence
ES3027182T3 (en)	2011-12-23	2025-06-13	Pfizer	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
AU2013211824B2 (en)	2012-01-27	2017-06-01	Gliknik Inc.	Fusion proteins comprising IgG2 hinge domains
US9447194B2 (en)	2012-02-13	2016-09-20	Seattle Children's Hospital	Bispecific chimeric antigen receptors and encoding polynucleotides thereof
IN2014DN07414A (en)	2012-02-22	2015-04-24	Univ Pennsylvania
WO2013126726A1 (en)	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Double transgenic t cells comprising a car and a tcr and their methods of use
EP2817331B1 (en)	2012-02-22	2023-08-30	The Trustees of the University of Pennsylvania	Use of the cd2 signaling domain in second-generation chimeric antigen receptors
CA2868121C (en)	2012-03-23	2021-06-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-mesothelin chimeric antigen receptors
RU2650805C2 (en)	2012-04-11	2018-04-17	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Chimeric antigen receptors targeting b-cell maturation antigen
US9156915B2 (en)	2012-04-26	2015-10-13	Thomas Jefferson University	Anti-GCC antibody molecules
SG10201609210SA (en)	2012-05-03	2016-12-29	Hutchinson Fred Cancer Res	Enhanced affinity t cell receptors and methods for making the same
CN110511278B (en)	2012-05-07	2024-08-09	达特茅斯大学理事会	Anti-B7-H6 antibodies, fusion proteins, and methods of use thereof
EP3828197B1 (en)	2012-05-22	2024-10-02	The United States of America, as represented by the Secretary, Department of Health and Human Services	Pharmaceutical composition comprising host cells encoding anti-ny-eso-1 t cell receptors
HK1209100A1 (en)	2012-05-22	2016-03-24	基因泰克有限公司	N-substituted benzamides and their use in the treatment of pain
ES2962571T3 (en)	2012-05-25	2024-03-19	Cellectis	Methods to modify allogeneic and immunosuppression-resistant T cells for immunotherapy
JP6494507B2 (en)	2012-06-01	2019-04-03	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	High affinity monoclonal antibody against glypican-3 and use thereof
EP2878670B1 (en)	2012-06-08	2019-08-07	Kinki University	Antibody against transporter and use thereof
JP5863585B2 (en)	2012-07-11	2016-02-16	三菱電機株式会社	Transistor characteristic calculation device using large signal equivalent circuit model
WO2014011996A1 (en)	2012-07-13	2014-01-16	The Trustees Of The University Of Pennsylvania	Methods of assessing the suitability of transduced t cells for administration
PT2872171T (en)	2012-07-13	2021-03-31	Univ Pennsylvania	TOXICITY MANAGEMENT FOR ANTITUMORAL CARS ACTIVITY
KR20150029714A (en)	2012-07-13	2015-03-18	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Enhancing activity of car t cells by co-introducing a bispecific antibody
AU2013289970A1 (en)	2012-07-13	2015-01-22	The Trustees Of The University Of Pennsylvania	Compositions and methods for regulating CAR T cells
CN102775500A (en)	2012-08-03	2012-11-14	郑骏年	Chimeric antigen receptor iRGD-scFv (G250)-CD8-CD28-CD137-CD3zeta and application thereof
IL269270B (en)	2012-08-20	2022-07-01	Hutchinson Fred Cancer Res	Method and preparations for cellular immunotherapy
EP3327037B1 (en)	2012-08-21	2019-10-09	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Mesothelin domain-specific monoclonal antibodies and use thereof
RU2663725C2 (en)	2012-09-04	2018-08-08	Селлектис	Multi-chain chimeric antigen receptor and uses thereof
SMT202000103T1 (en)	2012-09-14	2020-05-08	The U S A As Represented By The Secretary Department Of Health And Human Services	T cell receptors recognizing mhc class ii-restricted mage-a3
US9416190B2 (en)	2012-09-27	2016-08-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Mesothelin antibodies and methods for eliciting potent antitumor activity
US9365641B2 (en)	2012-10-01	2016-06-14	The Trustees Of The University Of Pennsylvania	Compositions and methods for targeting stromal cells for the treatment of cancer
CN112458057A (en)	2012-10-02	2021-03-09	纪念斯隆-凯特琳癌症中心	Compositions and methods for immunotherapy
US9598489B2 (en)	2012-10-05	2017-03-21	The Trustees Of The Univeristy Of Pennsylvania	Human alpha-folate receptor chimeric antigen receptor
US10117896B2 (en)	2012-10-05	2018-11-06	The Trustees Of The University Of Pennsylvania	Use of a trans-signaling approach in chimeric antigen receptors
JP6401704B2 (en)	2012-10-10	2018-10-10	サンガモセラピューティクス，インコーポレイテッド	Compounds that modify T cells and uses thereof
WO2014059248A1 (en)	2012-10-12	2014-04-17	Philadelphia Health & Education Corporation D/B/A/ Drexel	Mir-155 enhancement of cd8+ t cell immunity
UY35103A (en)	2012-10-29	2014-05-30	Glaxo Group Ltd	2-REPLACED CEFEM COMPOUNDS
WO2014099671A1 (en)	2012-12-20	2014-06-26	Bluebird Bio, Inc.	Chimeric antigen receptors and immune cells targeting b cell malignancies
EP3653212B1 (en)	2012-12-20	2023-04-26	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
US9511092B2 (en)	2013-01-28	2016-12-06	St. Jude Children's Research Hospital, Inc.	Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
JP6467661B2 (en)	2013-02-06	2019-02-13	セルジーンコーポレイション	Modified T lymphocytes with improved specificity
JO3529B1 (en)	2013-02-08	2020-07-05	Amgen Res Munich Gmbh	Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
EP3881868B1 (en)	2013-02-15	2023-09-27	The Regents Of The University Of California	Chimeric antigen receptor and methods of use thereof
KR102685501B1 (en)	2013-02-20	2024-07-17	노파르티스 아게	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
US9434935B2 (en)	2013-03-10	2016-09-06	Bellicum Pharmaceuticals, Inc.	Modified caspase polypeptides and uses thereof
US9499855B2 (en)	2013-03-14	2016-11-22	Elwha Llc	Compositions, methods, and computer systems related to making and administering modified T cells
US9402888B2 (en)	2013-03-14	2016-08-02	The Wistar Institute Of Anatomy And Biology	Methods and compositions for treating cancer
US9587237B2 (en)	2013-03-14	2017-03-07	Elwha Llc	Compositions, methods, and computer systems related to making and administering modified T cells
US9944690B2 (en)	2013-03-14	2018-04-17	Bellicum Pharmaceuticals, Inc.	Methods for controlling T cell proliferation
ES2790420T3 (en)	2013-03-14	2020-10-27	Scripps Research Inst	Conjugates of antibodies and targeting agents uses of the same
US9561291B2 (en)	2013-03-15	2017-02-07	Imre Kovesdi	Methods of targeting T-cells to tumors
CA2907397C (en)	2013-03-15	2022-11-22	Anthrogenesis Corporation	Modified t lymphocytes
US9446105B2 (en)	2013-03-15	2016-09-20	The Trustees Of The University Of Pennsylvania	Chimeric antigen receptor specific for folate receptor β
US9393268B2 (en)	2013-03-15	2016-07-19	Thomas Jefferson University	Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same
ES2769574T3 (en)	2013-03-15	2020-06-26	Michael C Milone	Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9657105B2 (en)	2013-03-15	2017-05-23	City Of Hope	CD123-specific chimeric antigen receptor redirected T cells and methods of their use
UY35468A (en)	2013-03-16	2014-10-31	Novartis Ag	CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
WO2014160627A1 (en)	2013-03-25	2014-10-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
EP3974520A1 (en)	2013-05-14	2022-03-30	Board of Regents, The University of Texas System	Human application of engineered chimeric antigen receptor (car) t-cells
CA2910489A1 (en)	2013-05-15	2014-11-20	Sangamo Biosciences, Inc.	Methods and compositions for treatment of a genetic condition
AU2014268364A1 (en)	2013-05-24	2015-12-10	Board Of Regents, The University Of Texas System	Chimeric antigen receptor-targeting monoclonal antibodies
ES2645393T3 (en)	2013-05-29	2017-12-05	Cellectis	T lymphocyte manipulation methods for immunotherapy using the RNA-guided Cas nuclease system
ES2883131T3 (en)	2013-05-29	2021-12-07	Cellectis	Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system
AU2014274916B2 (en)	2013-06-05	2019-10-31	Bellicum Pharmaceuticals, Inc.	Methods for inducing partial apoptosis using caspase polypeptides
WO2014200891A1 (en)	2013-06-11	2014-12-18	THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES	Her2-specific monoclonal antibodies and conjugates thereof
CN105492016B (en)	2013-06-25	2024-12-06	瓦西尼斯公司	Application of semaphorin-4D inhibitory molecules combined with immunomodulatory therapy to inhibit tumor growth and metastasis
CA2922670C (en)	2013-08-30	2022-11-29	Board Of Regents, The University Of Texas System	Administration of kynurenine depleting enzymes for tumor therapy
US20150073154A1 (en)	2013-09-11	2015-03-12	Equip, Llc	Discrete PEG Based Dyes
WO2015054691A2 (en)	2013-10-11	2015-04-16	The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services	Tem8 antibodies and their use
JP6734774B2 (en)	2013-10-15	2020-08-05	ザスクリプスリサーチインスティテュート	Peptide chimeric antigen receptor T cell switch and uses thereof
KR102357968B1 (en)	2013-10-15	2022-02-03	더 스크립스 리서치 인스티튜트	Chimeric antigen receptor t cell switches and uses thereof
US10144770B2 (en)	2013-10-17	2018-12-04	National University Of Singapore	Chimeric receptors and uses thereof in immune therapy
EP3063175A4 (en)	2013-10-31	2017-06-21	Fred Hutchinson Cancer Research Center	Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
CA2936501A1 (en)*	2014-01-13	2015-07-16	Stephen J. Forman	Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
US10526406B2 (en)	2014-01-14	2020-01-07	Cellectis	Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
US9694033B2 (en)	2014-01-24	2017-07-04	The Cleveland Clinic Foundation	IL-9 secreting CD8+ Tc9 cells and methods of treating cancer
WO2015123527A1 (en)	2014-02-14	2015-08-20	Bellicum Pharmaceuticals, Inc.	Methods for activating t cells using an inducible chimeric polypeptide
AU2015218365A1 (en)	2014-02-14	2016-09-01	Immune Design Corp.	Immunotherapy of cancer through combination of local and systemic immune stimulation
CN106132436B (en)*	2014-02-21	2021-06-15	Ibc药品公司	Disease therapy by inducing an immune response to TROP-2 expressing cells
EP3110824A4 (en)	2014-02-28	2017-11-29	The Royal Institution for the Advancement of Learning / McGill University	Tc-ptp inhibitors as apc activators for immunotherapy
GB201403875D0 (en)	2014-03-05	2014-04-16	Cantargia Ab	Novel antibodies and uses thereof
KR101605421B1 (en)	2014-03-05	2016-03-23	국립암센터	A monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
EP3114217A4 (en)	2014-03-07	2017-09-20	Bellicum Pharmaceuticals, Inc.	Caspase polypeptides having modified activity and uses thereof
US20170081411A1 (en)	2014-03-15	2017-03-23	Novartis Ag	Regulatable chimeric antigen receptor
JP2017513818A (en)	2014-03-15	2017-06-01	ノバルティスアーゲー	Treatment of cancer using chimeric antigen receptors
WO2015157252A1 (en)	2014-04-07	2015-10-15	BROGDON, Jennifer	Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2015157299A2 (en)	2014-04-09	2015-10-15	Seattle Children's Hospital (Dba Seattle Children's Research Institute	Inhibition of lactate dehydrogenase 5 (ldh-5) binding, incorporation, internalization and/or endocytosis to immune cells
WO2015157399A1 (en)	2014-04-10	2015-10-15	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Transgene genetic tags and methods of use
CN106459924A (en)*	2014-04-23	2017-02-22	得克萨斯州大学系统董事会	Chimeric antigen receptors (CAR) for use in therapy and methods for making the same
WO2015167766A1 (en)	2014-04-29	2015-11-05	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies
US20170210818A1 (en)	2014-06-06	2017-07-27	The California Institute For Biomedical Research	Constant region antibody fusion proteins and compositions thereof
WO2015191874A1 (en)	2014-06-12	2015-12-17	Children's National Medical Center	Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use
RU2741120C2 (en)	2014-07-21	2021-01-22	Новартис Аг	Treating cancer using a chimeric antigenic cll-1 receptor
WO2016014576A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
AU2015292744C1 (en)	2014-07-21	2021-01-21	Novartis Ag	Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3699189A1 (en)	2014-08-08	2020-08-26	The Board of Trustees of the Leland Stanford Junior University	High affinity pd-1 agents and methods of use
WO2016025322A1 (en)	2014-08-09	2016-02-18	Purdue Research Foundation	Design and development of neurokinin-1 receptor-binding agent delivery conjugates
US20180080008A1 (en)	2014-08-12	2018-03-22	Anthrogenesis Corporation	Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
RU2020117196A (en)	2014-08-19	2020-10-15	Новартис Аг	CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS
WO2016036746A1 (en)	2014-09-02	2016-03-10	Bellicum Pharmaceuticals, Inc.	Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
EP3194433B1 (en)	2014-09-19	2019-05-22	City of Hope	Costimulatory chimeric antigen receptor t cells targeting il13r 2
WO2016054520A2 (en)	2014-10-03	2016-04-07	The California Institute For Biomedical Research	Engineered cell surface proteins and uses thereof
EP3204399B1 (en)	2014-10-09	2025-01-22	Seattle Children's Hospital, dba Seattle Children's Research Institute	Long poly (a) plasmids and methods for introduction of long poly (a) sequences into the plasmid
JP7023709B2 (en)	2014-10-14	2022-02-22	リプタイドバイオサイエンス，インコーポレイテッド	Peptides with anti-inflammatory properties
JP7523203B2 (en)	2014-10-31	2024-07-26	マサチューセッツインスティテュートオブテクノロジー	Delivery of biomolecules to immune cells
CN107207615A (en)*	2014-11-05	2017-09-26	得克萨斯州大学系统董事会	Genetically Modified Immune Effector Cells and Engineered Cells for Expansion of Immune Effector Cells
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
CA2964138C (en)	2014-11-14	2023-11-14	Massachusetts Institute Of Technology	Disruption and field enabled delivery of compounds and compositions into cells
MX381235B (en)	2014-11-17	2025-03-12	Cellectar Biosciences Inc	Phospholipide ether analogues as carriers for cancer-targeted drugs.
HK1251862A1 (en)	2014-12-02	2019-04-26	普拉斯派克特查特凯尔Rwmc有限责任公司	Methods and compositons for treating cancer
BR112017011893A2 (en)	2014-12-05	2018-07-24	City Of Hope	modified t cells at cs1-directed chimeric antigen receptor
WO2016100236A2 (en)	2014-12-15	2016-06-23	Bellicum Pharmaceuticals, Inc.	Methods for controlled elimination of therapeutic cells
DK3234145T3 (en)	2014-12-15	2019-08-19	Bellicum Pharmaceuticals Inc	PROCEDURE FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS
WO2016100232A1 (en)	2014-12-15	2016-06-23	The Regents Of The University Of California	Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
US20190054117A1 (en)	2014-12-19	2019-02-21	Novartis Ag	Dimerization switches and uses thereof
EP4368704A3 (en)	2014-12-24	2024-05-29	Autolus Limited	Cell
CA2972597A1 (en)	2014-12-29	2016-07-07	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
EP3240551A4 (en)	2014-12-31	2018-08-08	Anthrogenesis Corporation	Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
US9765330B1 (en)	2015-01-09	2017-09-19	Nant Holdings Ip, Llc	Compositions and methods for reduction of allograft recognition and rejection
WO2016132366A1 (en)	2015-02-18	2016-08-25	Enlivex Therapeutics Ltd.	Combination immune therapy and cytokine control therapy for cancer treatment
CN117886949A (en)	2015-02-24	2024-04-16	加利福尼亚大学董事会	Binding-triggered transcriptional switches and methods of use thereof
KR102133857B1 (en)	2015-03-02	2020-07-20	이노베이티브 셀룰러 테라퓨틱스 코퍼레이션 리미티드	Reduction of immune tolerance induced by PDD-L1
WO2016149254A1 (en)	2015-03-17	2016-09-22	Chimera Bioengineering, Inc.	Smart car devices, de car polypeptides, side cars and uses thereof
US20180079824A1 (en)	2015-03-18	2018-03-22	Baylor College Of Medicine	HER2/ErbB2 Chimeric Antigen Receptor
US9717745B2 (en)	2015-03-19	2017-08-01	Zhejiang DTRM Biopharma Co. Ltd.	Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US10800828B2 (en)	2015-03-26	2020-10-13	The Scripps Research Institute	Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
WO2016154628A1 (en)	2015-03-26	2016-09-29	Xiuli Wang	Bi-specific targeted chimeric antigen receptor t cells
GB201505305D0 (en)	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US20180100026A1 (en)	2015-04-15	2018-04-12	California Institute For Biomedical Research	Optimized chimeric receptor t cell switches and uses thereof
WO2016168773A2 (en)	2015-04-15	2016-10-20	The California Institute For Biomedical Research	Optimized pne-based chimeric receptor t cell switches and uses thereof
ES2852973T3 (en)	2015-05-15	2021-09-14	Hope City	Chimeric antigen receptor compositions
DK3297664T3 (en)	2015-05-19	2020-12-07	Morphogenesis Inc	CANCERVACCINE INCLUDING MRNA CODING FOR AN M-LIKE PROTEIN
CN114344321A (en)	2015-05-28	2022-04-15	凯德药业股份有限公司	Methods of conditioning patients for T-cell therapy
US20160361360A1 (en)	2015-06-12	2016-12-15	Immunomedics, Inc.	Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US9663756B1 (en)	2016-02-25	2017-05-30	Flodesign Sonics, Inc.	Acoustic separation of cellular supporting materials from cultured cells
JP2018518972A (en)	2015-06-26	2018-07-19	ユニバーシティオブサザンカリフォルニア	Masking chimeric antigen receptor T cells for tumor specific activation
GB201514328D0 (en)	2015-08-12	2015-09-23	Sigmoid Pharma Ltd	Compositions
GB201514875D0 (en)	2015-08-20	2015-10-07	Autolus Ltd	Receptor
GB201514874D0 (en)	2015-08-20	2015-10-07	Autolus Ltd	Cell
WO2017035362A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
US10525082B2 (en)	2015-09-09	2020-01-07	Seattle Children's Hospital	Genetic engineering of macrophages for immunotherapy
US9790467B2 (en)	2015-09-22	2017-10-17	Qt Holdings Corp	Methods and compositions for activation or expansion of T lymphocytes
HK1258726A1 (en)*	2015-09-28	2019-11-15	Regents Of The University Of Minnesota	Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
ES2803728T3 (en)	2015-10-05	2021-01-29	Prec Biosciences Inc	Genetically modified cells comprising a modified human T-cell receptor alpha constant region gene
US11466097B2 (en)	2015-10-06	2022-10-11	City Of Hope	Chimeric antigen receptors targeted to PSCA
GB201518817D0 (en)	2015-10-23	2015-12-09	Autolus Ltd	Cell
GB201518816D0 (en)	2015-10-23	2015-12-09	Autolus Ltd	Receptor
EP3370743A4 (en)	2015-11-05	2019-04-24	City of Hope	METHODS OF PREPARING LYMPHOCYTES FOR ADOPTIVE TRANSFER THERAPY OF T-CELLS
US20180327781A1 (en)	2015-11-09	2018-11-15	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Novel rna-based vector system for transient and stable gene expression
TWI724056B (en)	2015-11-19	2021-04-11	美商卡默森屈有限公司	Inhibitors of cxcr2
TWI734715B (en)	2015-11-19	2021-08-01	美商卡默森屈有限公司	Modulators of chemokine receptors
JP2019506143A (en)	2015-12-14	2019-03-07	ベリカムファーマシューティカルズ，インコーポレイテッド	Dual control for activation and elimination of therapeutic cells
US9849092B2 (en)	2015-12-21	2017-12-26	Gholam A. Peyman	Early cancer detection and enhanced immunotherapy
EP3397756B1 (en)	2015-12-30	2023-03-08	Novartis AG	Immune effector cell therapies with enhanced efficacy
AU2017205197B2 (en)	2016-01-08	2021-05-20	The Regents Of The University Of California	Conditionally active heterodimeric polypeptides and methods of use thereof
EP3402885A4 (en)	2016-01-11	2019-07-03	The Board of Trustees of the Leland Stanford Junior University	CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION
WO2017123548A1 (en)	2016-01-14	2017-07-20	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
AU2017213661B2 (en)	2016-02-05	2022-06-02	City Of Hope	Administration of engineered T cells for treatment of cancers in the central nervous system
GB201602571D0 (en)	2016-02-12	2016-03-30	Autolus Ltd	Signalling system
GB201602563D0 (en)	2016-02-12	2016-03-30	Autolus Ltd	Signalling system
JP2019508036A (en)	2016-02-16	2019-03-28	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Immunotherapeutic compositions and methods
EP3416690A4 (en)	2016-02-19	2020-02-19	City of Hope	SPECIFIC APTAMER
US11111505B2 (en)	2016-03-19	2021-09-07	Exuma Biotech, Corp.	Methods and compositions for transducing lymphocytes and regulating the activity thereof
CU24649B1 (en)	2016-03-19	2023-02-13	Exuma Biotech Corp	RECOMBINANT RETROVIRUSES INCOMPETENT OF REPLICATION FOR THE TRANSDUCTION OF LYMPHOCYTES AND REGULATED EXPANSION THEREOF
EP4015536A1 (en)*	2016-03-22	2022-06-22	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	Early intervention methods to prevent or ameliorate toxicity
US12144850B2 (en)	2016-04-08	2024-11-19	Purdue Research Foundation	Methods and compositions for car T cell therapy
US11446398B2 (en)	2016-04-11	2022-09-20	Obsidian Therapeutics, Inc.	Regulated biocircuit systems
KR102356864B1 (en)	2016-06-06	2022-02-04	시티 오브 호프	BAFF-R Target Chimeric Antigen Receptor-Modified T Cells and Uses Thereof
EP3464374B1 (en)	2016-06-06	2025-08-06	City of Hope	Baff-r antibodies and uses thereof
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor
GB201610515D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Cell
US9567399B1 (en)	2016-06-20	2017-02-14	Kymab Limited	Antibodies and immunocytokines
CN115404196A (en)	2016-07-13	2022-11-29	哈佛学院院长等	Antigen-presenting cell mimic scaffold and methods for its preparation and use
BR112019002646A2 (en)	2016-08-09	2019-10-08	Hope City	chimeric poxvirus compositions and uses thereof
US9642906B2 (en)	2016-09-16	2017-05-09	Baylor College Of Medicine	Generation of HPV-specific T-cells
EP3529353A4 (en)	2016-10-19	2020-05-13	City of Hope	Use of triplex cmv vaccine in car t cell therapy
KR102613430B1 (en)	2016-10-19	2023-12-18	더 스크립스 리서치 인스티튜트	Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor-interacting domains and uses thereof
WO2018075813A1 (en)	2016-10-19	2018-04-26	City Of Hope	Use of endogenous viral vaccine in chimeric antigen receptor t cell therapy
US10617720B2 (en)	2016-10-20	2020-04-14	Miltenyi Biotech, GmbH	Chimeric antigen receptor specific for tumor cells
WO2018080541A1 (en)	2016-10-31	2018-05-03	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogennous foxp3 gene
US20200095547A1 (en)	2016-12-02	2020-03-26	Darya ALIZADEH	Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
MX2019006631A (en)	2016-12-12	2019-11-12	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells.
AU2017378153B2 (en)	2016-12-13	2024-03-28	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
EP3336107A1 (en)	2016-12-15	2018-06-20	Miltenyi Biotec GmbH	Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
JP7078937B2 (en)	2016-12-21	2022-06-01	ダンマークステクニスクユニバーシテット	Antigen presentation scaffold for manipulating immune cells
WO2018148224A1 (en)	2017-02-07	2018-08-16	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
EP4600267A2 (en)	2017-02-17	2025-08-13	Purdue Research Foundation	Targeted ligand-payload based drug delivery for cell therapy
US11850262B2 (en)	2017-02-28	2023-12-26	Purdue Research Foundation	Compositions and methods for CAR T cell therapy
US20200405881A1 (en)	2017-03-06	2020-12-31	University Of Washington	Cell based methods and compositions for therapeutic agent delivery and treatments using same
US20200276318A1 (en)	2017-03-06	2020-09-03	University Of Washington	Engineered cells and agent compositions for therapeutic agent delivery and treatments using same
EP3595681A4 (en)	2017-03-16	2020-12-16	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	TRANSPLANTABLE CELL-BASED IMMUNOTHERAPY FOR THE LONG-TERM ADMINISTRATION OF THERAPEUTIC PROTEINS
JP2020511498A (en)	2017-03-20	2020-04-16	シティ・オブ・ホープＣｉｔｙｏｆＨｏｐｅ	CS1-targeting chimeric antigen receptor-modified T cells for treatment of AL amyloidosis
EP3624814A4 (en)	2017-05-17	2021-02-24	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	GENERATION OF MAMMALIAN T-CELL ACTIVATION INDUCTIBLE SYNTHETIC PROMOTORS (SYN + PRO) TO IMPROVE T-CELL THERAPY
CN111246882A (en)	2017-08-01	2020-06-05	希望之城	Anti-IL1RAP antibody
WO2019033050A1 (en)	2017-08-11	2019-02-14	City Of Hope	Bispecific antigen-binding molecule
SG11202006886VA (en)	2018-01-22	2020-08-28	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Methods of use for car t cells
CN111936518A (en)	2018-02-06	2020-11-13	西雅图儿童医院（Dba西雅图儿童研究所）	Fluorescein-specific CARs exhibiting optimal T cell function for FL-PLE labeled tumors
CA3091674A1 (en)	2018-02-23	2019-08-29	Endocyte, Inc.	Sequencing method for car t cell therapy
EP3775231A2 (en)	2018-04-12	2021-02-17	Umoja Biopharma, Inc.	Viral vectors and packaging cell lines
EP3784259A4 (en)	2018-04-27	2021-12-29	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	Rapamycin resistant cells
EP3833363A4 (en)	2018-08-06	2022-05-11	Seattle Children's Hospital (DBA Seattle Children's Research Institute)	METHODS AND COMPOSITIONS FOR STIMULATION OF CHEMERA ANTIGEN RECEPTOR T LYMPHOCYTES WITH HAPTENE LABELED CELLS
EP3833400A4 (en)	2018-08-07	2022-06-15	Purdue Research Foundation	Rejuvenation of car t cell
US20220017920A1 (en)	2018-11-21	2022-01-20	Umoja Biopharma, Inc.	Multicistronic vector for surface engineering lentiviral particles
CN114340643A (en)	2019-07-05	2022-04-12	普渡研究基金会	Design and efficient synthesis of lipid-fluorescein conjugates for CAR-T cell therapy
WO2021055641A1 (en)	2019-09-17	2021-03-25	Purdue Research Foundation	Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases
JP2022553200A (en)	2019-10-16	2022-12-22	ウモジャバイオファーマ，インコーポレイテッド	Retroviral vectors for universal receptor therapy
IL295129A (en)	2020-01-30	2022-09-01	Umoja Biopharma Inc	Bispecific transduction enhancer
IL295063A (en)	2020-02-04	2022-09-01	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Chimeric antigen receptors (car) against dinitrophenol
US20230172981A1 (en)	2020-02-04	2023-06-08	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Methods and compositions for stimulation of chimeric antigen receptor t cells with hapten labelled cells
WO2021178887A1 (en)	2020-03-06	2021-09-10	Purdue Research Foundation	Methods, compounds, and compositions for modifying car-t cell activity
CN116323656A (en)	2020-07-16	2023-06-23	优莫佳生物制药股份有限公司	Gating adapter targeting receptors
CN116745427A (en)	2020-11-20	2023-09-12	优莫佳生物制药股份有限公司	Vector systems for delivery of various polynucleotides and their uses
WO2022164935A1 (en)	2021-01-27	2022-08-04	Umoja Biopharma, Inc.	Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
WO2023240248A2 (en)	2022-06-09	2023-12-14	Umoja Biopharma, Inc.	Compositions and methods for nk cell differentiation

2019
- 2019-01-22SGSG11202006886VApatent/SG11202006886VA/enunknown
- 2019-01-22BRBR112020014913-6Apatent/BR112020014913A2/enunknown
- 2019-01-22JPJP2020561571Apatent/JP7417542B2/enactiveActive
- 2019-01-22CACA3089319Apatent/CA3089319A1/enactivePending
- 2019-01-22CACA3089051Apatent/CA3089051A1/enactivePending
- 2019-01-22EPEP19741309.9Apatent/EP3743082A4/enactivePending
- 2019-01-22USUS16/253,562patent/US11779602B2/enactiveActive
- 2019-01-22EPEP19740881.8Apatent/EP3740217A4/enactivePending
- 2019-01-22JPJP2020561570Apatent/JP7549303B2/enactiveActive
- 2019-01-22CNCN202411859267.6Apatent/CN120154716A/enactivePending
- 2019-01-22AUAU2019209428Apatent/AU2019209428B2/enactiveActive
- 2019-01-22USUS16/253,572patent/US11311576B2/enactiveActive
- 2019-01-22WOPCT/US2019/014478patent/WO2019144095A1/ennot_activeCeased
- 2019-01-22CNCN201980020371.7Apatent/CN112292138A/enactivePending
- 2019-01-22AUAU2019209432Apatent/AU2019209432A1/enactivePending
- 2019-01-22TWTW108102429Apatent/TW201940182A/enunknown
- 2019-01-22CNCN201980021107.5Apatent/CN112055595B/enactiveActive
- 2019-01-22WOPCT/US2019/014472patent/WO2019144091A1/ennot_activeCeased
2020
- 2020-07-17ILIL276131Apatent/IL276131A/enunknown
2022
- 2022-01-27USUS17/586,067patent/US20220257652A1/enactivePending
2023
- 2023-08-31USUS18/459,302patent/US12269862B2/enactiveActive
2024
- 2024-08-20JPJP2024138411Apatent/JP2024174886A/enactivePending

Publication number	Publication date
US11311576B2 (en)	2022-04-26
US20220257652A1 (en)	2022-08-18
EP3740217A1 (en)	2020-11-25
CA3089319A1 (en)	2019-07-25
CN120154716A (en)	2025-06-17
JP7417542B2 (en)	2024-01-18
JP2024174886A (en)	2024-12-17
JP2021511826A (en)	2021-05-13
TW201940182A (en)	2019-10-16
US12269862B2 (en)	2025-04-08
JP2021512147A (en)	2021-05-13
EP3740217A4 (en)	2021-11-10
BR112020014913A2 (en)	2020-12-08
US20190224237A1 (en)	2019-07-25
WO2019144091A1 (en)	2019-07-25
US11779602B2 (en)	2023-10-10
AU2019209428A1 (en)	2020-07-30
WO2019144095A1 (en)	2019-07-25
AU2019209428B2 (en)	2025-06-26
AU2019209432A1 (en)	2020-08-06
EP3743082A1 (en)	2020-12-02
CN112292138A (en)	2021-01-29
US20190255109A1 (en)	2019-08-22
CN112055595B (en)	2024-12-17
EP3743082A4 (en)	2021-11-03
IL276131A (en)	2020-08-31
CA3089051A1 (en)	2019-07-25
CN112055595A (en)	2020-12-08
US20240075069A1 (en)	2024-03-07
JP7549303B2 (en)	2024-09-11

Publication	Publication Date	Title
IL276131A (en)	2020-08-31	Methods of use for car t cells
CA185738S (en)	2019-12-27	Car
IL266316A (en)	2019-06-30	Anti-bcma car t cell compositions
SG11202100616VA (en)	2021-03-30	Rejuvenation of car t cell
CA185453S (en)	2019-12-16	Car
IL278016A (en)	2020-11-30	Method for enhancing the suppressive properties of treg cells
GB2527164B (en)	2018-08-15	Apparatus, kits and methods for the prediction of onset of sepsis
EP3352784A4 (en)	2019-06-26	CELLS DIRECTED AGAINST FLT3 FOR IMMUNOTHERAPY
CA187973S (en)	2020-07-30	Car
GB2545180B (en)	2018-08-29	Apparatus for the manufacture of battery components
IL266111A (en)	2019-06-30	Methods for promoting t cells response
SG11202103745WA (en)	2021-05-28	Method for activation/proliferation of t cells
EP3230117C0 (en)	2023-06-07	Method and arrangement for charging of vehicle accumulators
SG11202008503UA (en)	2020-10-29	Storage method of feces
SG11202010335WA (en)	2020-11-27	Techniques for performing secure operations
IL264205A (en)	2019-02-28	Cell compositions for tissue regeneration
PL3638021T3 (en)	2025-06-09	Methods for preservation of cells
HK40042208A (en)	2021-08-27	Methods of use for car t cells
HK40038932A (en)	2021-07-02	Methods of use for car t cells
HK40100598A (en)	2024-05-03	Rejuvenation of car t cell
GB201506044D0 (en)	2015-05-27	Methods for determining the effect of an agent on tissue stem cells
HK40121105A (en)	2025-09-05	Compositions and methods for car t cell therapy
HK40053085A (en)	2022-01-28	Rejuvenation of car t cell
GB201810835D0 (en)	2018-08-15	Methods of use
HK40003756A (en)	2020-04-17	Methods and compositions for car t cell therapy

Movatterモバイル変換

SG11202006886VA - Methods of use for car t cells - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (7)

Publications (1)

Family

ID=67299784

Family Applications (1)

Country Status (11)

Families Citing this family (19)

Family Cites Families (402)

Also Published As

Similar Documents